Ali Nowrouzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ali Nowrouzi has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Hanno Glimm
Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT), NCT/University Cancer Center Dresden, a Partnership Between German Cancer Research Center (DKFZ), Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden University of Technology (TUD), and Helmholtz-Zentrum Dresden-Rossendorf, 01307 Dresden, Germany
2 shared publications - Christof von Kalle
Clinical Study Center, Berlin Institute of Health at Charité – Universitätsmedizin Berlin , Berlin 10117
1 shared publication - Claudia Scholl
Department of Internal Medicine III, Ulm University, Ulm, Germany
1 shared publication Manfred Schmidt
1 shared publication- Manfred Schmidt
Department of Translational Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany
1 shared publication Priya Chudasama
1 shared publication
Latest Publications
- Open Access
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S54-S55
134. Gene Editing Approaches for Investigating Therapy-Resistance in Soft-Tissue Sarcoma
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S54-S55
Open Access134. Gene Editing Approaches for Investigating Therapy-Resistance in Soft-Tissue Sarcoma
- Open Access
Retroviral Vectors: Post Entry Events and Genomic Alterations
The curative potential of retroviral vectors for somatic gene therapy has been demonstrated impressively in several clinical trials leading to sustained long-term correction of the underlying genetic defect. Preclinical studies and clinical monitoring of gene modified hematopoietic stem and progenitor cells in patients have shown that biologically relevant vector induced side effects, ranging from in vitro immortalization to clonal dominance and oncogenesis in vivo, accompany therapeutic efficiency of integrating retroviral gene transfer systems. Most importantly, it has been demonstrated that the genotoxic potential is not identical among all retroviral vector systems designed for clinical application. Large scale viral integration site determination has uncovered significant differences in the target site selection of retrovirus subfamilies influencing the propensity for inducing genetic alterations in the host genome. In this review we will summarize recent insights gained on the mechanisms of insertional mutagenesis based on intrinsic target site selection of different retrovirus families. We will also discuss examples of side effects occurring in ongoing human gene therapy trials and future prospectives in the field.
Open AccessRetroviral Vectors: Post Entry Events and Genomic Alterations
The curative potential of retroviral vectors for somatic gene therapy has been demonstrated impressively in several clinical trials leading to sustained long-term correction of the underlying genetic defect. Preclinical studies and clinical monitoring of gene modified hematopoietic stem and progenitor cells in patients have shown that biologically relevant vector induced side effects, ranging from in vitro immortalization to clonal dominance and oncogenesis in vivo, accompany therapeutic efficiency of integrating retroviral gene transfer systems. Most importantly, it has been demonstrated that the genotoxic potential is not identical among all retroviral vector systems designed for clinical application. Large scale viral integration site determination has uncovered significant differences in the target site selection of retrovirus subfamilies influencing the propensity for inducing genetic alterations in the host genome. In this review we will summarize recent insights gained on the mechanisms of insertional mutagenesis based on intrinsic target site selection of different retrovirus families. We will also discuss examples of side effects occurring in ongoing human gene therapy trials and future prospectives in the field.